Thymopentin
Thymopentin (TP-5) is a synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) corresponding to residues 32-36 of thymopoietin, the active site responsible for T-cell differentiation. It is studied for immunodeficiency, HIV adjunct therapy, and autoimmune disease management.
Thymopentin (TP-5) is a synthetic pentapeptide with the sequence Arg-Lys-Asp-Val-Tyr, representing the minimal active fragment (residues 32-36) of the 49-amino acid thymic hormone thymopoietin. First characterized by Gideon Goldstein and colleagues at the Memorial Sloan Kettering Cancer Center in the 1970s, TP-5 retains the full biological activity of the parent protein in promoting T-cell differentiation.
Overview
Thymopentin was developed as a practical therapeutic alternative to full-length thymopoietin, which is rapidly degraded in vivo and difficult to produce at scale. Structure-activity studies by Goldstein's group demonstrated that the pentapeptide sequence at positions 32-36 constitutes the active site of thymopoietin, capable of inducing T-cell differentiation markers in precursor cells at nanomolar concentrations. Despite its extremely short serum half-life (approximately 30 seconds), TP-5 exerts sustained biological effects lasting days to weeks, likely through rapid triggering of intracellular signaling cascades that persist after the peptide is degraded.
TP-5 entered clinical trials in the 1980s and was evaluated in several controlled studies for primary immunodeficiency, AIDS, rheumatoid arthritis, and allergic diseases. While it showed promising results in multiple indications, it was not ultimately approved by the FDA, partly due to the difficulty of demonstrating clear clinical endpoints in immunomodulation trials of that era. It remains available in some countries, particularly in China, where it is marketed for immune reconstitution.
Mechanism of Action
Thymopentin induces T-cell differentiation by mimicking the active site of thymopoietin, triggering a rapid signaling cascade in thymocytes and peripheral T cells:
T-cell differentiation: TP-5 promotes the maturation of pre-T cells into functional T lymphocytes by inducing the expression of surface differentiation markers (CD2, CD3, CD4, CD8). It acts on early thymocyte precursors, driving their commitment to the T-cell lineage and subsequent maturation through the cortical and medullary compartments of the thymus.
Intracellular signaling: Despite its very short half-life, TP-5 activates intracellular second messenger systems including cAMP elevation and protein kinase C activation within seconds of receptor binding. These signals trigger downstream gene expression programs that persist long after the peptide is cleared, explaining the sustained immunological effects.
Cytokine modulation: TP-5 enhances IL-2 production and IL-2 receptor expression on T cells, promoting autocrine T-cell proliferation. It also modulates interferon-gamma and IL-4 production, influencing the Th1/Th2 balance.
NK cell enhancement: Beyond T-cell effects, TP-5 augments natural killer cell activity and enhances antibody-dependent cellular cytotoxicity (ADCC), broadening its immunomodulatory profile.
Neuroendocrine effects: Like thymopoietin itself, TP-5 has effects at the neuromuscular junction and can influence neuromuscular transmission, although these effects are minimal at therapeutic doses for immunomodulation.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Primary Immunodeficiency
Clinical trials in children with primary immunodeficiency disorders demonstrated that TP-5 administration (50 mg subcutaneously three times weekly) improved T-cell numbers, normalized T-cell subset ratios, and enhanced lymphocyte proliferative responses. In a controlled trial of patients with DiGeorge syndrome and other thymic aplasia conditions, TP-5 partially reconstituted T-cell immunity and reduced infection frequency (Audhya et al., 1987).
Autoimmune Diseases
TP-5 has been studied in rheumatoid arthritis, where its immunomodulatory (rather than immunosuppressive) mechanism offers a theoretical advantage over conventional treatments. Clinical studies showed modest improvements in joint symptoms and inflammatory markers in patients receiving TP-5, though results were inconsistent across trials. The peptide has also been investigated in systemic lupus erythematosus with preliminary positive results.
Allergic Disease
TP-5 has been evaluated in atopic dermatitis and allergic rhinitis, where it was shown to reduce serum IgE levels and modulate the Th2-skewed cytokine profile characteristic of allergic conditions. These results suggest a potential role in rebalancing immune responses in atopic patients.
Alopecia Areata
A double-blind, placebo-controlled trial of TP-5 in alopecia areata (an autoimmune condition affecting hair follicles) demonstrated significant hair regrowth in the treatment group compared to placebo. The mechanism was attributed to modulation of the aberrant T-cell response against hair follicle autoantigens (Stiller et al., 1994).
HIV/AIDS Adjunct Therapy
Several clinical trials evaluated TP-5 as an adjunct to antiretroviral therapy in HIV-infected patients. A multicenter, placebo-controlled trial in 368 patients with ARC (AIDS-related complex) found that TP-5 (50 mg subcutaneously three times weekly for 6 months) was associated with delayed progression to AIDS and improved CD4+ T-cell stability compared to placebo, although the differences did not reach statistical significance for all endpoints (Gupta & Gruber, 1989).
Safety Profile
Thymopentin has been extensively evaluated in clinical trials involving over 1,000 patients, with an excellent safety record. The most common side effect is mild, transient pain or erythema at the injection site. Allergic reactions are rare. Importantly, TP-5 does not cause immunosuppression or autoimmune exacerbation at therapeutic doses, distinguishing it from many other immunomodulatory agents. No dose-limiting toxicities have been identified in clinical trials at doses up to 50 mg administered three times weekly for extended periods. The peptide's extremely short half-life contributes to its favorable safety profile, as systemic exposure is minimal.
Pharmacokinetic Profile
Thymopentin — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Molecular Structure
- Formula
- C12H16N2O9P+
- Weight
- 679.77 Da
- CAS
- 69558-55-0
- PubChem CID
- 6323387
- Exact Mass
- 363.0593 Da
- LogP
- -2.7
- TPSA
- 184 Ų
- H-Bond Donors
- 6
- H-Bond Acceptors
- 10
- Rotatable Bonds
- 8
- Complexity
- 689
Identifiers (SMILES, InChI)
InChI=1S/C12H15N2O9P/c1-6-11(17)8(4-14-9(12(18)19)2-10(15)16)7(3-13-6)5-23-24(20,21)22/h3-4,9,14H,2,5H2,1H3,(H,15,16)(H,18,19)(H2,20,21,22)/p+1/b8-4+
FQTKXBPGQPWGPV-XBXARRHUSA-OResearch Protocols
subcutaneous Injection
Research Primary Immunodeficiency Clinical trials in children with primary immunodeficiency disorders demonstrated that TP-5 administration (50 mg subcutaneously three times weekly) improved T-cell numbers, normalized T-cell subset ratios, and enhanced lymphocyte proliferative responses.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 50 mg | Once weekly | — |
Interactions
Peptide Interactions
Neuroendocrine effects: Like thymopoietin itself, TP-5 has effects at the neuromuscular junction and can influence neuromuscular transmission, although these effects are minimal at therapeutic doses for immunomodulation.
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (5)
- [1]Goldstein G et al Thymopentin and bursopoietin: induction of allograft rejection by selective T-cell and B-cell priming agents Science (1979)
- [2]Audhya T et al Thymopoietin biology and applications Ann N Y Acad Sci (1987)
- [3]Gupta S, Gruber SA Thymopentin (TP-5) in clinical immunology Thymus (1989)
- [4]Stiller MJ et al Thymopentin in the treatment of alopecia areata: a preliminary study J Am Acad Dermatol (1994)
- [5]Singh VK et al Immunomodulatory activity of thymopentin analogs in aging Int J Immunopharmacol (1998)
Thymalin
Thymalin is a thymus-derived dipeptide complex (Glu-Trp) developed in Russia for immune restoration, particularly in aging populations. It modulates T-cell differentiation, cytokine balance, and has been studied for its interactions with the pineal gland via the pineal-thymus axis.
Thymopoietin
Thymopoietin is a 49-amino acid thymic hormone discovered by Gideon Goldstein that induces T-cell differentiation and influences neuromuscular transmission. Its active fragment (residues 32-36) is the basis for the therapeutic peptide thymopentin (TP-5).